Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care.

Haas JS, Liang SY, Hassett MJ, Shiboski S, Elkin EB, Phillips KA.

Breast Cancer Res Treat. 2011 Nov;130(2):619-26. doi: 10.1007/s10549-011-1628-6. Epub 2011 Jun 17.

2.

Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.

Potosky AL, O'Neill SC, Isaacs C, Tsai HT, Chao C, Liu C, Ekezue BF, Selvam N, Kessler LG, Zhou Y, Schwartz MD.

Cancer. 2015 Nov 15;121(22):4062-70. doi: 10.1002/cncr.29621. Epub 2015 Aug 20.

3.

How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.

Marshall DA, Deal K, Bombard Y, Leighl N, MacDonald KV, Trudeau M.

BMJ Open. 2016 Jun 2;6(6):e010981. doi: 10.1136/bmjopen-2015-010981. Erratum in: BMJ Open. 2016 Jun 23;6(6):e010981corr1.

4.

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.

Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC.

J Clin Oncol. 2012 Jun 20;30(18):2218-26. doi: 10.1200/JCO.2011.38.5740. Epub 2012 May 14.

5.

The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.

MacDonald KV, Bombard Y, Deal K, Trudeau M, Leighl N, Marshall DA.

Eur J Cancer. 2016 Jul;61:85-93. doi: 10.1016/j.ejca.2016.03.077. Epub 2016 May 4.

PMID:
27155447
6.

Genomic testing and therapies for breast cancer in clinical practice.

Haas JS, Phillips KA, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M.

Am J Manag Care. 2011 May 1;17(5 Spec No):e174-81.

7.

Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65.

O'Neill SC, Isaacs C, Lynce F, Graham DM, Chao C, Sheppard VB, Zhou Y, Liu C, Selvam N, Schwartz MD, Potosky AL.

Breast Cancer Res. 2017 Mar 31;19(1):45. doi: 10.1186/s13058-017-0837-2.

8.

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.

Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L.

Health Technol Assess. 2013 Oct;17(44):1-302. doi: 10.3310/hta17440. Review.

9.

Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.

Schreuder K, Kuijer A, Rutgers EJT, Smorenburg CH, van Dalen T, Siesling S.

Eur J Cancer. 2017 Oct;84:270-277. doi: 10.1016/j.ejca.2017.07.042. Epub 2017 Aug 24.

PMID:
28844015
10.
11.

Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers.

Roberts MC, Dusetzina SB.

J Oncol Pract. 2015 Jul;11(4):273-7. doi: 10.1200/JOP.2015.003624. Epub 2015 Jun 23.

PMID:
26105668
12.

Association between genomic recurrence risk and well-being among breast cancer patients.

Retèl VP, Groothuis-Oudshoorn CG, Aaronson NK, Brewer NT, Rutgers EJ, van Harten WH.

BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295.

13.

Genomic testing and therapies for breast cancer in clinical practice.

Haas JS, Phillips KA, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M.

J Oncol Pract. 2011 May;7(3 Suppl):e1s-7s. doi: 10.1200/JOP.2011.000299.

14.

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W.

J Med Econ. 2013;16(1):30-40. doi: 10.3111/13696998.2012.722572. Epub 2012 Sep 11.

PMID:
22966753
15.

Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.

Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC.

J Natl Cancer Inst. 2006 Aug 16;98(16):1108-17.

PMID:
16912263
16.

Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.

Yang M, Rajan S, Issa AM.

Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22.

17.

Integrated gene expression profile predicts prognosis of breast cancer patients.

Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, Shao ZM.

Breast Cancer Res Treat. 2009 Jan;113(2):231-7. doi: 10.1007/s10549-008-9925-4. Epub 2008 Feb 16.

PMID:
18278552
18.

Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.

Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH.

JAMA Oncol. 2015 Nov;1(8):1098-109. doi: 10.1001/jamaoncol.2015.2722.

PMID:
26313372
19.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
20.

21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.

Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O'Regan RM.

Cancer. 2012 Feb 1;118(3):788-96. doi: 10.1002/cncr.26180. Epub 2011 Jun 30.

Supplemental Content

Support Center